|
|
Diabetes R & D Pipeline Report: DPP-4 InhibitorsPublished by: BioPolaris Published: Sep. 1, 2009 - 41 Pages Table of Contents
AbstractWith increasing incidence and prevalence of diabetes, not only in developed countries but also in countries of the third world, demand for cheap and efficient products for the treatment of diabetes is growing. With perspective of over 400 million people suffering from diabetes worldwide in 2030, production and sales of approved therapeutic products will increase enormously. However, existing therapies are not enough effective. According to the the US Centers for Disease Control and Prevention’s National Health and Nutrition Examination Survey, approximately 60% of patients with diabetes do not achieve their target blood sugar levels with their current treatment. That means that demand for new and more efficient therapies for diabetes will rise and intensify in the coming years.Research and development pipeline of investigational products for the treatment of diabetes reflects this future demand. According to results of analysis performed by BioPolaris there is currently over 250 new products undergoing development for the treatment of diabetes, with over 10 distinct classes. DPP-4 (dipeptidyl peptidase 4) inhibitors belong to the class of anti-diabetic compounds that act by suppressing degradation of hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide) which act by stimulating insulin secretion from pancreatic beta cells and, in the case of GLP-1, production of glucose in liver. The number of DPP-4 inhibitors is already on market, including sitagliptin (Januvia®), approved by the US Food and Drug Administration (FDA) in October 2006, vildagliptin (Galvus®, LAF237), approved in the EU in February 2008 and saxagliptin (ONGLYZA™, BMS-477118), approved by the FDA in July 2009. DPP-4 inhibitors R & D pipeline is one of the largest between various diabetes pipelines. It is mature, well balanced pipeline with products in advanced but also in the early stages of development. BioPolaris’ analysis reveals that total of 22 DPP-4 inhibitors are presently undergoing development, including one approved in the EU and in Phase III clinical trials in the USA, three in Phase III, nine in Phase II, four in Phase I clinical trials, one with approved Investigational Drug (IND) application by the US Food and Drug Administration (FDA) and four in preclinical stage of development. Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||